Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis

By  

CNS Spectrums, Vol. 22, Iss. 2, 2017-03 ,pp. : 228-235

Cambridge University Press

Access to resources Recommend Favorite

Measures of the DSM–5 mixed-features specifier of major depressive disorder

By  

CNS Spectrums, Vol. 22, Iss. 2, 2017-01 ,pp. : 196-202

Cambridge University Press

Access to resources Recommend Favorite

Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study

By  

CNS Spectrums, Vol. 22, Iss. 2, 2017-03 ,pp. : 236-245

Cambridge University Press

Access to resources Recommend Favorite

Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension

By  

CNS Spectrums, Vol. 22, Iss. 2, 2017-03 ,pp. : 220-227

Cambridge University Press

Access to resources Recommend Favorite

Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension—CORRIGENDUM

By  

CNS Spectrums, Vol. 22, Iss. 4, 2017-05 ,pp. : 373-373

Cambridge University Press

Access to resources Recommend Favorite